Evidence map›Paper›PMID 42078937›Full record

ArticleFrontiers in pharmacology2026

Licochalcone A mitigates cisplatin-induced nephrotoxicity by inhibiting ferroptosis and mitochondrial dysfunction via the Nrf2/GPX4 axis.

Mo Han, Feihu Zhang, Mengyuan Li, Qixiang Zhang, Kaidi Shen, Depeng Zhang, Huanke Xu, Fang Zhou, Xinyu Wang

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Mo Han *Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Feihu Zhang *Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Mengyuan Li *Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Qixiang ZhangKey Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Kaidi ShenKey Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Depeng ZhangKey Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Huanke XuKey Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Fang ZhouKey Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Xinyu WangDepartment of Pharmacy and Institute of Clinical Pharmacology, General Hospital of Ningxia Medical University, Yinchuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cisplatin-induced nephrotoxicity is a major dose-limiting complication of chemotherapy. However, effective protective strategies remain limited. Licochalcone A (LicoA), a flavonoid isolated from Glycyrrhiza inflata, exhibits multi-target bioactivity against oxidative stress, inflammation, and metabolic disorders. Methods: Results: LicoA significantly ameliorated cisplatin-induced renal dysfunction and attenuated the progression from acute kidney injury (AKI) to chronic kidney disease (CKD), as evidenced by reduced tubular injury and fibrosis. Metabolomic analysis revealed that LicoA restored energy metabolism and glutathione homeostasis. LicoA effectively alleviated cisplatin-induced ferroptosis by inhibiting Fe Conclusion: LicoA alleviated cisplatin-induced renal injury by activating the Nrf2/GPX4 axis, thereby suppressing ferroptosis and mitigating mitochondrial damage. These findings highlight the therapeutic potential of LicoA in preventing cisplatin nephrotoxicity and impeding the AKI-to-CKD transition.

Indexed as

cisplatin-induced nephrotoxicityferroptosisLicoAmitochondrionNrf2

Identifiers

PMID42078937
PMCPMC13132868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.